Vertex Pharmaceuticals Overview
Vertex Pharmaceuticals Target Price
Analysts' 12-month price predictions for VRTX.
Share Price
$424.99
Average Target Price
$499.00
17.4% upside
17.4% upside4 analysts in the last 4 months
High: $545 | Low: $456
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2025-04-22 | Cantor Fitzgerald | $535 | 25.9% upside |  |
| 2025-01-31 | BMO CapitalEvan Seigerman | $545 | 28.2% upside | |
| 2025-01-30 | Wells FargoMohit Bansal | $460 | 8.2% upside | |
| 2025-01-10 | Morgan StanleyTerence Flynn | $456 | 7.3% upside | |
| 2024-12-19 | RBC CapitalBrian Abrahams | $400 |  5.9% downside | |
| 2024-12-09 | JefferiesMichael Yee | $550 | 29.4% upside | |
| 2024-11-05 | OppenheimerHartaj Singh | $540 | 27.1% upside | |
| 2024-11-05 | RBC CapitalBrian Abrahams | $451 | 6.1% upside | |
| 2024-10-22 | Canaccord GenuityWhitney Ijem | $361 | 15.1% downside | |
| 2024-10-21 | BMO CapitalEvan David Seigerman | $566 | 33.2% upside | |
| 2024-10-21 | Goldman SachsSalveen Richter | $598 | 40.7% upside | |
| 2024-10-14 | Bank of America SecuritiesGeoff Meacham | $541 | 27.3% upside | |
| 2024-10-09 | RBC CapitalBrian Abrahams | $437 | 2.8% upside | |
| 2024-08-05 | Truist FinancialJoon Lee | $550 | 29.4% upside | |
| 2024-08-05 | OppenheimerHartaj Singh | $550 | 29.4% upside | |
| 2024-08-05 | Wolfe ResearchAndy Chen | $576 | 35.5% upside | |
| 2024-08-02 | H.C. WainwrightAndrew Fein | $600 | 41.2% upside | |
| 2024-06-17 | Argus ResearchJasper Hellweg | $550 | 29.4% upside | |
| 2024-06-11 | RBC CapitalBrian Abrahams | $421 | 0.9% downside | |
| 2024-05-31 | BMO CapitalEvan David Seigerman | $500 | 17.6% upside | |
| 2024-05-07 | Raymond JamesChristopher Raymond | $456 | 7.3% upside | |
| 2024-05-07 | RBC CapitalBrian Abrahams | $424 | 0.2% downside | |
| 2024-04-11 | H.C. WainwrightAndrew Fein | $462 | 8.7% upside | |
| 2024-04-11 | Evercore ISILiisa Bayko | $438 | 3.1% upside | |
| 2023-02-08 | Morgan Stanley | $285 | 32.9% downside | |
| 2023-02-08 | H.C. Wainwright | $326 | 23.3% downside | |
| 2023-02-08 | Leerink Partners | $365 | 14.1% downside | |
| 2022-11-17 | Argus Research | $340 | 20% downside | |
| 2022-08-08 | Morgan Stanley | $253 | 40.5% downside | |
| 2022-08-05 | H.C. Wainwright | $300 | 29.4% downside | |
| 2022-07-12 | Cantor FitzgeraldOlivia Brayer | $365 | 14.1% downside | |
| 2022-07-11 | Stifel NicolausPaul Matteis | $240 | 43.5% downside | |
| 2022-07-02 | Argus ResearchJasper Hellweg | $280 | 34.1% downside | |
| 2022-06-13 | Cowen & Co. | $310 | 27.1% downside | |
| 2022-05-03 | Morgan StanleyMatthew Harrison | $250 | 41.2% downside | |
| 2022-04-22 | Piper Sandler | $249 | 41.4% downside | |
| 2022-04-06 | OppenheimerHartaj Singh | $350 | 17.6% downside | |
| 2022-03-22 | Robert W. BairdBrian Skorney | $240 | 43.5% downside | |
| 2022-03-22 | BMO CapitalEvan Seigerman | $274 | 35.5% downside | |
| 2022-01-27 | J.P. MorganCory Kasimov | $288 | 32.2% downside | |
| 2022-01-27 | Wolfe ResearchAndrew Galler | $282 | 33.6% downside | |
| 2022-01-27 | Morgan StanleyMatthew Harrison | $208 | 51.1% downside | |
| 2022-01-27 | JefferiesMichael Yee | $275 | 35.3% downside | |
| 2022-01-24 | Cowen & Co.Phil Nadeau | $300 | 29.4% downside | |
| 2021-12-02 | Leerink PartnersGeoff Porges | $175 | 58.8% downside | |
| 2021-12-01 | GuggenheimDebjit Chattopadhyay | $286 | 32.7% downside | |
| 2021-11-02 | Bank of America SecuritiesGeoff Meacham | $275 | 35.3% downside | |
| 2021-06-11 | BarclaysGena Wang | $285 | 32.9% downside | |
| 2021-06-11 | Cantor FitzgeraldAlethia Young | $281 | 33.9% downside | |
| 2021-05-12 | UBSColin Bristow | $279 | 34.4% downside | |